News > Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

The experimental drug, fosgonimeton, failed to reach statistical significance in a test that measures cognition and other functions, compared to placebo at 26 weeks. Chief Medical Officer Javier Martin said that the lack of clinical decline in the placebo group, combined with the short duration of the study, may have impacted the trial's ability to translate the effect of fosgonimeton into meaningful benefit. The trial was conducted on 312 patients.